NCT01540565 2019-07-23
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)